Insilico Medicine expands synthetic lethality
New York, Might 5, 2022/PRNewswire/-- Insilico Drugs (“Insilico”), a clinical-stage end-to-end synthetic intelligence (AI)-driven drug discovery firm, right now introduced ...
Tag: Insilico
Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders
Insilico Drugs Nominates Its USP1 Small Molecule Inhibitor as a Preclinical Candidate for Tumors with Homologous Recombination Deficiency NEW YORK, ...
Insilico Medicine's AI zeroes in on new drug targets for aging, age-related diseases – FierceBiotech
Insilico Medicine's AI zeroes in on new drug targets for aging, age-related diseases FierceBiotech Source link
Insilico Announces Successful Completion of Phase 0 Microdose Trial and Initiates Phase I Clinical Trial for its First AI-discovered Anti-fibrotic Product Candidate with Novel Target
The double-blind, placebo managed single and a number of ascending dose Section I scientific trial will consider the protection, tolerability, ...
Press release: Fosun-backed Drugmaker Insilico Names Anti-Cancer Drug Candidate
Insilico Medication and Fosun Pharma are working collectively on IND-enabling research to advance PCCs within the QPCTL program to scientific ...
POPULAR NEWS
EDITOR'S PICK
